Dependence on Honghai commissions
Over 97% of annual revenue came from one sales agency relationship, so termination or repricing would sharply reduce income.
- Scope
- Revenue and earnings concentration
- Materiality
- High
Longduoduo Co Ltd
Longduoduo Co Ltd is a U.S.-listed company with operating subsidiaries in Inner Mongolia and Beijing that generates revenue from two main activities: direct healthcare services and commissions earned as a sales agent for Inner Mongolia Honghai Health Management Co., Ltd. The business has shifted heavily toward agency commissions, making it more of a healthcare distribution and referral platform than a pure service clinic operator.
16,2 %
97,9 %
10,8 %
−42,3 %
2.18
2.18
| % | |
|---|---|
| Direct healthcare services | 3% In-clinic or direct patient services such as autohemotherapy, assay, and PRP offerings. |
| Sales agency commissions | 97% Commission income earned from selling Honghai-administered preventive healthcare solutions. |
The company serves consumers in Inner Mongolia and nearby markets who purchase preventive or alternative healthcare...
- Direct healthcare patientssecondary
Individuals purchasing in-house healthcare services such as autohemotherapy, PRP, assay and related treatments.
- Honghai-referred customersprimary
Consumers who buy preventive healthcare solutions administered by Honghai, generating commissions for Longduoduo.
- Local discretionary health spenderssecondary
Households in Inner Mongolia and Beijing that spend on non-essential healthcare services when economic conditions allow.
Operations are concentrated in Inner Mongolia, China, with entities in Huhhot, Ulanqab, Baotou and Ordos, plus one...
- •Operating entities are based in Inner Mongolia cities and Beijing
- •Core business activity is concentrated in Huhhot, Ulanqab, Baotou and Ordos
- •Revenue is generated in China, not the United States
- •U.S. capital markets are important for future financing plans
- •PRC listing and cybersecurity rules can affect access to external capital
Management is focused on funding growth, improving operating policies, and balancing customer prepayments with working...
01
Secure external financing accessshort-term
Growth depends on capital for expansion, but PRC listing approvals may delay or block fundraising.
02
Stabilize operating cash flowshort-term
The company has limited scale and needs cash generation to fund obligations and expansion.
03
Reduce dependence on one counterpartymedium-term
Honghai commissions represent the vast majority of revenue, creating concentration risk.
The biggest risk is customer and revenue concentration: most revenue comes from Honghai commissions, so any disruption...
PRC overseas listing approval risk
Future financing through U.S. markets may require CSRC approval, which could be delayed or denied.
- Scope
- Capital access
- Materiality
- High
Weak discretionary health spending
Management cited a softer economic environment and lower customer health expenditures.
- Scope
- Demand and revenue volatility
- Materiality
- High
Going-concern and liquidity pressure
The company expects to rely on operations, public offering proceeds or debt financing to fund growth and obligations.
- Scope
- Cash flow and solvency
- Materiality
- High
China regulatory and cybersecurity uncertainty
PRC rules on overseas listings and data review could affect quotation and compliance costs.
- Scope
- Regulatory compliance
- Materiality
- Medium
Revenue recognition for commissions and healthcare services
Revenue mix and gross profit
Deferred revenue and customer prepayments
Working capital and revenue timing
Allowance for doubtful accounts
Receivables and earnings
Impairment and contingency estimates
Potential earnings volatility
: 28.4.2026